bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 12 from Spatially Distinct Reprogramming of the Tumor Microenvironment Based On Tumor Invasion in Diffuse-Type Gastric Cancers
Authors: Jeong Hye Young , Ham In-Hye , Lee Sung Hak , Ryu Daeun , Son Sang-Yong , Han Sang-Uk , Kim Tae-Min , Hur Hoon
Published: April 2023

Non-malignant epithelial cell subclusters
Supplementary Figure 11 from Spatially Distinct Reprogramming of the Tumor Microenvironment Based On Tumor Invasion in Diffuse-Type Gastric Cancers
Authors: Jeong Hye Young , Ham In-Hye , Lee Sung Hak , Ryu Daeun , Son Sang-Yong , Han Sang-Uk , Kim Tae-Min , Hur Hoon
Published: April 2023

PC subclusters
Supplementary Figure S1 from Establishment of Patient-Derived Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response
Authors: Yebra Mayra , Bhargava Shruti , Kumar Avi , Burgoyne Adam M. , Tang Chih-Min , Yoon Hyunho , Banerjee Sudeep , Aguilera Joseph , Cordes Thekla , Sheth Vipul , Noh Sangkyu , Ustoy Rowan , Li Sam , Advani Sunil J. , Corless Christopher L. , Heinrich Michael C. , Kurzrock Razelle , Lippman Scott M. , Fanta Paul T. , Harismendy Olivier , Metallo Christian , Sicklick Jason K.
Published: April 2023

Fig. S1. Characteristics of patient-derived mSDH GIST models. A. Representative micrographs of colonies formed by mSDH GIST models on soft agar after 3-5 weeks. B. Quantitative measurements for number of colonies observed in soft agar after 3-5 weeks of seeding mSDH GIST models at indicated densities: 2000, 4000, 8000, 16000 cells/well. C. Representative micrographs of colonies formed by mSDH GIST models on 1% methylcellulose after 2 weeks. D. Quantitative measurements for number of colonies observed in 1% methylcellulose after 2 weeks of seeding 50,000 cells/well mSDH GIST models.
Supplementary Figure 1 from Spatially Distinct Reprogramming of the Tumor Microenvironment Based On Tumor Invasion in Diffuse-Type Gastric Cancers
Authors: Jeong Hye Young , Ham In-Hye , Lee Sung Hak , Ryu Daeun , Son Sang-Yong , Han Sang-Uk , Kim Tae-Min , Hur Hoon
Published: April 2023

Performance of batch-effect corrections
Supplementary Data from Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models
Authors: Campian Jian L. , Ghosh Subhajit , Kapoor Vaishali , Yan Ran , Thotala Sukrutha , Jash Arijita , Hu Tong , Mahadevan Anita , Rifai Kasem , Page Logan , Lee Byung Ha , Ferrando-Martinez Sara , Wolfarth Alexandra A. , Yang Se Hwan , Hallahan Dennis , Chheda Milan G. , Thotala Dinesh
Published: April 2023

Supplementary Data from Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models
Figure S7 from Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma
Authors: Waldschmidt Johannes M. , Kloeber Jake A. , Anand Praveen , Frede Julia , Kokkalis Antonis , Dimitrova Valeriya , Potdar Sayalee , Nair Monica S. , Vijaykumar Tushara , Im Nam Gyu , Guillaumet-Adkins Amy , Chopra Nitish , Stuart Hannah , Budano Lillian , Sotudeh Noori , Guo Guangwu , Grassberger Clemens , Yee Andrew J. , Laubach Jacob P. , Richardson Paul G. , Anderson Kenneth C. , Raje Noopur S. , Knoechel Birgit , Lohr Jens G.
Published: April 2023

Copy number variations in dabrafenib-resistant U266 single-cell clones as compared to baseline
Figure S6 from Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma
Authors: Waldschmidt Johannes M. , Kloeber Jake A. , Anand Praveen , Frede Julia , Kokkalis Antonis , Dimitrova Valeriya , Potdar Sayalee , Nair Monica S. , Vijaykumar Tushara , Im Nam Gyu , Guillaumet-Adkins Amy , Chopra Nitish , Stuart Hannah , Budano Lillian , Sotudeh Noori , Guo Guangwu , Grassberger Clemens , Yee Andrew J. , Laubach Jacob P. , Richardson Paul G. , Anderson Kenneth C. , Raje Noopur S. , Knoechel Birgit , Lohr Jens G.
Published: April 2023

Dabrafenib sensitivity in dabrafenib-resistant U266 single-cell clones as compared to baseline
Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
Authors: van Linde Myra E. , Labots Mariette , Brahm Cyrillo G. , Hovinga Koos E. , De Witt Hamer Philip C. , Honeywell Richard J. , de Goeij-de Haas Richard , Henneman Alex A. , Knol Jaco C. , Peters Godefridus J. , Dekker Henk , Piersma Sander R. , Pham Thang V. , Vandertop William P. , Jiménez Connie R. , Verheul Henk M.W.
Published: April 2023

Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
Figure S14 from Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma
Authors: Waldschmidt Johannes M. , Kloeber Jake A. , Anand Praveen , Frede Julia , Kokkalis Antonis , Dimitrova Valeriya , Potdar Sayalee , Nair Monica S. , Vijaykumar Tushara , Im Nam Gyu , Guillaumet-Adkins Amy , Chopra Nitish , Stuart Hannah , Budano Lillian , Sotudeh Noori , Guo Guangwu , Grassberger Clemens , Yee Andrew J. , Laubach Jacob P. , Richardson Paul G. , Anderson Kenneth C. , Raje Noopur S. , Knoechel Birgit , Lohr Jens G.
Published: April 2023

Rotenone sensitivity in dabrafenib-persistent vs. naïve single-cell clones
Supplementary Date from Multi-scale Pan-cancer Integrative Analyses Identify the STAT3-VSIR Axis as a Key Immunosuppressive Mechanism in Head and Neck Cancer
Authors: Katabathula Ramachandra , Joseph Peronne , Singh Salendra , Zhao Songzhu , Kumar Bhavna , Gaule Patricia , Pan Quintin , Old Matthew , Tuck David P. , Varadan Vinay
Published: April 2023

Supplementary Date from Multi-scale Pan-cancer Integrative Analyses Identify the STAT3-VSIR Axis as a Key Immunosuppressive Mechanism in Head and Neck Cancer
Supplementary Figure S2 from Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors
Authors: Hollebecque Antoine , Chung Hyun C. , de Miguel Maria J. , Italiano Antoine , Machiels Jean-Pascal , Lin Chia-Chi , Dhani Neesha C. , Peeters Marc , Moreno Victor , Su Wu-Chou , Chow Kay Hoong , Galvao Violeta R. , Carlsen Michelle , Yu Danni , Szpurka Anna M. , Zhao Yumin , Schmidt Shelly L. , Gandhi Leena , Xu Xiaojian , Bang Yung-Jue
Published: April 2023

Figure S2. Overall survival
Supplementary Fig S1 from Transcriptomic Profiling Identifies a Risk Stratification Signature for Predicting Peritoneal Recurrence and Micrometastasis in Gastric Cancer
Authors: Lee In-Seob , Lee Heonyi , Hur Hoon , Kanda Mitsuro , Yook Jeong-Hwan , Kim Byung-Sik , Woo Yanghee , Kodera Yasuhiro , Kim Kwangsoo , Goel Ajay
Published: April 2023

Study design and overall workflow
Figure S6 from Unbiased Detection of Driver Mutations in Extramammary Paget Disease
Authors: Ishida Yoshihiro , Kakiuchi Nobuyuki , Yoshida Kenichi , Inoue Yoshikage , Irie Hiroyuki , Kataoka Tatsuki R. , Hirata Masahiro , Funakoshi Takeru , Matsushita Shigeto , Hata Hiroo , Uchi Hiroshi , Yamamoto Yuki , Fujisawa Yasuhiro , Fujimura Taku , Saiki Ryunosuke , Takeuchi Kengo , Shiraishi Yuichi , Chiba Kenichi , Tanaka Hiroko , Otsuka Atsushi , Miyano Satoru , Kabashima Kenji , Ogawa Seishi
Published: April 2023

FGFR1 fluorescence in situ hybridization images
Figure S7 from Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study
Authors: Delaidelli Alberto , Dunham Christopher , Santi Mariarita , Negri Gian Luca , Triscott Joanna , Zheludkova Olga , Golanov Andrey , Ryzhova Marina , Okonechnikov Konstantin , Schrimpf Daniel , Stichel Damian , Ellison David W. , von Deimling Andreas , Kool Marcel , Pfister Stefan M. , Ramaswamy Vijay , Korshunov Andrey , Taylor Michael D. , Sorensen Poul H.
Published: April 2023

Fig S7. Estimated prediction error for overall survival based on models without TPD52 (blue lines) or with TPD52 (yellow lines), compared with the Kaplan-Meier benchmark (grey line). Survival models based on clinical variables (age, sex, metastasis status, resection and therapy) were trained on the BH cohort and utilized to predict survival in the BCCH
Table 2 from Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials
Authors: Furtner Julia , Weller Michael , Weber Michael , Gorlia Thierry , Nabors Burt , Reardon David A. , Tonn Joerg C. , Stupp Roger , Preusser Matthias
Published: April 2023

Collinearity Statistics Coefficients
Supplementary Table 3 from Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials
Authors: Furtner Julia , Weller Michael , Weber Michael , Gorlia Thierry , Nabors Burt , Reardon David A. , Tonn Joerg C. , Stupp Roger , Preusser Matthias
Published: April 2023

Relative TMT loss between the baseline MRI and the first follow-up MR examination and the associated OS.
Figure S3 from Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study
Authors: Delaidelli Alberto , Dunham Christopher , Santi Mariarita , Negri Gian Luca , Triscott Joanna , Zheludkova Olga , Golanov Andrey , Ryzhova Marina , Okonechnikov Konstantin , Schrimpf Daniel , Stichel Damian , Ellison David W. , von Deimling Andreas , Kool Marcel , Pfister Stefan M. , Ramaswamy Vijay , Korshunov Andrey , Taylor Michael D. , Sorensen Poul H.
Published: April 2023

Fig S3. A) Density plot representing the distribution of the percentage of positive cell for tumors in the BH cohort. As described in the manuscript text, three broad categories of tumors were identified: TPD52 negative (no positive cells, 54.9% of tumors), TPD52 low (=> 20 % and < 50% positive cells, 34.1% of tumors), or TPD52 high (=> 50% positive cells, 11.0% of tumors) B) Density plot representing the distribution of tumors in the BH cohort according to TPD52 mRNA expression. Two broad categories of tumors can be identified: TPD52 low (mostly corresponding to tumors TPD52 negative by IHC) and TPD52 high (mostly corresponding to IHC positive tumors). C) Heatmap and contingency table representing the correlation between high TPD52 mRNA expression and IHC positivity for the cases in the BH cohort. D) Maximally selected rank statistics analysis of the optimal TPD52 percentage cut-off for univariate survival analysis. Higher values on the y axis indicate lower log-rank p values in univariate survival analysis. Significance level according to the improved Bonferroni inequality corresponds to y < 0.001, so every possible cut-off for TPD52 percentage positivity results in significant differences in univariate survival analysis. The optimal cut-off (> 40% positive cells = high) corresponds to the => 50% cut-off utilized in Figs 2D-F. E) Representative IHC pictures for tumors negative, or with < 50% and => 50% positive cells. Scale bar = 50 um. TPD52 IHC was not prognostic in SHH tumors.
Figure S2 from Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma
Authors: Hannan Raquibul , Mohamad Osama , Diaz de Leon Alberto , Manna Subrata , Pop Laurentiu M. , Zhang Ze , Mannala Samantha , Christie Alana , Christley Scott , Monson Nancy , Ishihara Dan , Hsu Eric J. , Ahn Chul , Kapur Payal , Chen Mingyi , Arriaga Yull , Courtney Kevin , Cantarel Brandi , Wakeland Edward K. , Fu Yang-Xin , Pedrosa Ivan , Cowell Lindsay , Wang Tao , Margulis Vitaly , Choy Hak , Timmerman Robert D. , Brugarolas James
Published: April 2023

Supplementary Fig. S2. Trend lines showing pre- and post-treatment values and pre-to-post-treatment change for the Non-Clinically Benefiting (NCB) and Clinically Benefiting (CB) patient groups.
Figure S1 from Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma
Authors: Hannan Raquibul , Mohamad Osama , Diaz de Leon Alberto , Manna Subrata , Pop Laurentiu M. , Zhang Ze , Mannala Samantha , Christie Alana , Christley Scott , Monson Nancy , Ishihara Dan , Hsu Eric J. , Ahn Chul , Kapur Payal , Chen Mingyi , Arriaga Yull , Courtney Kevin , Cantarel Brandi , Wakeland Edward K. , Fu Yang-Xin , Pedrosa Ivan , Cowell Lindsay , Wang Tao , Margulis Vitaly , Choy Hak , Timmerman Robert D. , Brugarolas James
Published: April 2023

Supplementary Fig. S1: T cell receptor (TCR) repertoire for circulating and tumor associated T cells status and pre-to-post-treatment change for the Non-Clinically Benefiting (NCB) and Clinically Benefiting (CB) patient groups.
Supplementary Table from Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE
Authors: LeNoue-Newton Michele L. , Chen Sheau-Chiann , Stricker Thomas , Hyman David M. , Blauvelt Natalie , Bedard Philippe L. , Meric-Bernstam Funda , Punglia Rinaa S. , Schrag Deborah , Lepisto Eva M. , Andre Fabrice , Smyth Lillian , Dogan Semih , Yu Celeste , Wathoo Chetna , Levy Mia , Eli Lisa D. , Xu Feng , Mann Grace , Lalani Alshad S. , Ye Fei , Micheel Christine M. , Arnedos Monica
Published: April 2023

Supplementary Table from Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE
Supplementary Data from Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
Authors: Harding James J. , Moreno Victor , Bang Yung-Jue , Hong Min Hee , Patnaik Amita , Trigo José , Szpurka Anna M. , Yamamoto Noboru , Doi Toshihiko , Fu Siqing , Calderon Boris , Velez de Mendizabal Nieves , Calvo Emiliano , Yu Danni , Gandhi Leena , Liu Zhuqing Tina , Galvao Violeta Regnier , Leow Ching Ching , de Miguel Maria J.
Published: April 2023

Supplemental Tables
Supplementary Figure from Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE
Authors: LeNoue-Newton Michele L. , Chen Sheau-Chiann , Stricker Thomas , Hyman David M. , Blauvelt Natalie , Bedard Philippe L. , Meric-Bernstam Funda , Punglia Rinaa S. , Schrag Deborah , Lepisto Eva M. , Andre Fabrice , Smyth Lillian , Dogan Semih , Yu Celeste , Wathoo Chetna , Levy Mia , Eli Lisa D. , Xu Feng , Mann Grace , Lalani Alshad S. , Ye Fei , Micheel Christine M. , Arnedos Monica
Published: April 2023

Supplementary Figure from Natural History and Characteristics of ERBB2-mutated Hormone Receptor–positive Metastatic Breast Cancer: A Multi-institutional Retrospective Case–control Study from AACR Project GENIE
Figure S1 from Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
Authors: Harding James J. , Moreno Victor , Bang Yung-Jue , Hong Min Hee , Patnaik Amita , Trigo José , Szpurka Anna M. , Yamamoto Noboru , Doi Toshihiko , Fu Siqing , Calderon Boris , Velez de Mendizabal Nieves , Calvo Emiliano , Yu Danni , Gandhi Leena , Liu Zhuqing Tina , Galvao Violeta Regnier , Leow Ching Ching , de Miguel Maria J.
Published: April 2023

Study Design
Supplementary Figure from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Authors: Bergamino Milana A. , Morani Gabriele , Parker Joel , Schuster Eugene F. , Leal Mariana F. , López-Knowles Elena , Tovey Holly , Bliss Judith M. , Robertson John F.R. , Smith Ian E. , Dowsett Mitch , Cheang Maggie C.U.
Published: April 2023

Supplementary Figure from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Supplementary Data from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Authors: Bergamino Milana A. , Morani Gabriele , Parker Joel , Schuster Eugene F. , Leal Mariana F. , López-Knowles Elena , Tovey Holly , Bliss Judith M. , Robertson John F.R. , Smith Ian E. , Dowsett Mitch , Cheang Maggie C.U.
Published: April 2023

Supplementary Data from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Supplementary Table 1 from Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma
Authors: Livingston Michael B. , Jagosky Megan H. , Robinson Myra M. , Ahrens William A. , Benbow Jennifer H. , Farhangfar Carol J. , Foureau David M. , Maxwell Deirdre M. , Baldrige Emily A. , Begic Xhevahire , Symanowski James T. , Steuerwald Nury M. , Anderson Colin J. , Patt Joshua C. , Kneisl Jeffrey S. , Kim Edward S.
Published: April 2023

Stopping rule boundariesâ€¯for theâ€¯incidence of patients with at least one severe or life-threatening toxicity.â€¯
Supplementary Material from Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma
Authors: Livingston Michael B. , Jagosky Megan H. , Robinson Myra M. , Ahrens William A. , Benbow Jennifer H. , Farhangfar Carol J. , Foureau David M. , Maxwell Deirdre M. , Baldrige Emily A. , Begic Xhevahire , Symanowski James T. , Steuerwald Nury M. , Anderson Colin J. , Patt Joshua C. , Kneisl Jeffrey S. , Kim Edward S.
Published: April 2023

Study inclusion and exclusion criteria.
Supplemental Table 4 from Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma
Authors: Livingston Michael B. , Jagosky Megan H. , Robinson Myra M. , Ahrens William A. , Benbow Jennifer H. , Farhangfar Carol J. , Foureau David M. , Maxwell Deirdre M. , Baldrige Emily A. , Begic Xhevahire , Symanowski James T. , Steuerwald Nury M. , Anderson Colin J. , Patt Joshua C. , Kneisl Jeffrey S. , Kim Edward S.
Published: April 2023

Treatment Emergent Adverse Events Attributed to Pembrolizumab, Any Grade.
Supplementary Figure from Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation
Authors: Kumar Tapsi , Hobbs Evie , Yang Fei , Chang Jeffrey T. , Contreras Alejandro , Cuentas Edwin Roger Parra , Garber Haven , Lee Sanghoon , Lu Yiling , Scoggins Marion E. , Adrada Beatriz E. , Whitman Gary J. , Arun Banu K. , Mittendorf Elizabeth A. , Litton Jennifer K.
Published: April 2023

Supplementary Figure from Tumor Immune Microenvironment Changes by Multiplex Immunofluorescence Staining in a Pilot Study of Neoadjuvant Talazoparib for Early-Stage Breast Cancer Patients with a Hereditary BRCA Mutation
Supplementary Tables from Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma
Authors: Gao Yajing , Päivinen Pekka , Tripathi Sushil , Domènech-Moreno Eva , Wong Iris P.L. , Vaahtomeri Kari , Nagaraj Ashwini S. , Talwelkar Sarang S. , Foretz Marc , Verschuren Emmy W. , Viollet Benoit , Yan Yan , Mäkelä Tomi P.
Published: April 2023

Supplementary Tables S1-S2
Supplementary Figures from Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma
Authors: Gao Yajing , Päivinen Pekka , Tripathi Sushil , Domènech-Moreno Eva , Wong Iris P.L. , Vaahtomeri Kari , Nagaraj Ashwini S. , Talwelkar Sarang S. , Foretz Marc , Verschuren Emmy W. , Viollet Benoit , Yan Yan , Mäkelä Tomi P.
Published: April 2023

Supplementary Figures S1-S6
Supplementary Table from IL15 and Anti–PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors
Authors: Chen Wei , Bamford Richard N. , Edmondson Elijah F. , Waldmann Thomas A.
Published: April 2023

Supplementary Table from IL15 and Anti–PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors
Supplementary table 7 from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
Authors: Cao Yue , Haring Catherine T. , Brummel Collin , Bhambhani Chandan , Aryal Madhava , Lee Choonik , Heft Neal Molly , Bhangale Apurva , Gu Wenjin , Casper Keith , Malloy Kelly , Sun Yilun , Shuman Andrew , Prince Mark E. , Spector Matthew E. , Chinn Steven , Shah Jennifer , Schonewolf Caitlin , McHugh Jonathan B. , Mills Ryan E. , Tewari Muneesh , Worden Francis P. , Swiecicki Paul L. , Mierzwa Michelle , Brenner J. Chad
Published: April 2023

Detailed summary of HPV to host genome integration sites identified by targeted capture sequencing analysis of FFPE tumor specimens
Supplementary Data from First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Authors: Siu Lillian L. , Wang Ding , Hilton John , Geva Ravit , Rasco Drew , Perets Ruth , Abraham Anson K. , Wilson Douglas C. , Markensohn Julia F. , Lunceford Jared , Suttner Leah , Siddiqi Shabana , Altura Rachel A. , Maurice-Dror Corinne
Published: April 2023

Supplementary Data from First-in-Class Anti-immunoglobulin–like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors
Supplementary table 6 from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
Authors: Cao Yue , Haring Catherine T. , Brummel Collin , Bhambhani Chandan , Aryal Madhava , Lee Choonik , Heft Neal Molly , Bhangale Apurva , Gu Wenjin , Casper Keith , Malloy Kelly , Sun Yilun , Shuman Andrew , Prince Mark E. , Spector Matthew E. , Chinn Steven , Shah Jennifer , Schonewolf Caitlin , McHugh Jonathan B. , Mills Ryan E. , Tewari Muneesh , Worden Francis P. , Swiecicki Paul L. , Mierzwa Michelle , Brenner J. Chad
Published: April 2023

Detailed summary of HPV16 genome somatic INDELs identified by targeted capture sequencing analysis of FFPE tumor specimens
Supplementary Figure from Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
Authors: Grisic Ana-Marija , Xiong Wenyuan , Tanneau Lénaïg , Jönsson Siv , Friberg Lena E. , Karlsson Mats O. , Dai Haiqing , Zheng Jenny , Girard Pascal , Khandelwal Akash
Published: April 2023

Supplementary Figure from Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
Supplementary Figure from NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy
Authors: Otani Yoshihiro , Yoo Ji Young , Lewis Cole T. , Chao Samantha , Swanner Jessica , Shimizu Toshihiko , Kang Jin Muk , Murphy Sara A. , Rivera-Caraballo Kimberly , Hong Bangxing , Glorioso Joseph C. , Nakashima Hiroshi , Lawler Sean E. , Banasavadi-Siddegowda Yeshavanth , Heiss John D. , Yan Yuanqing , Pei Guangsheng , Caligiuri Michael A. , Zhao Zhongming , Chiocca E. Antonio , Yu Jianhua , Kaur Balveen
Published: April 2023

Supplementary Figure from NOTCH-Induced MDSC Recruitment after oHSV Virotherapy in CNS Cancer Models Modulates Antitumor Immunotherapy
Supplemental Figure 1 from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Authors: Sheng Xinan , Chen Haige , Hu Bin , Yao Xudong , Liu Ziling , Yao Xin , Guo Hongqian , Hu Yi , Ji Zhigang , Luo Hong , Shi Benkang , Liu Jiyan , Wu Jin , Zhou FangJian , He Zhisong , Fan Jinhai , Wang Weifeng , Feng Hui , Yao Sheng , Keegan Patricia , Huang Yiran , Guo Jun
Published: April 2023

Cross correlation study among different PD-L1 IHC staining antibodies.
Supplementary Tables from Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma
Authors: Chahoud Jad , Gleber-Netto Frederico O. , McCormick Barrett Z. , Rao Priya , Lu Xin , Guo Ming , Morgan Maggaret B. , Chu Randy A. , Martinez-Ferrer Magaly , Eterovic Agda Karina , Pickering Curtis R. , Pettaway Curtis A.
Published: April 2023

Supplementary Tables S1 - S5
Supplementary Figure S4 from Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma
Authors: Chahoud Jad , Gleber-Netto Frederico O. , McCormick Barrett Z. , Rao Priya , Lu Xin , Guo Ming , Morgan Maggaret B. , Chu Randy A. , Martinez-Ferrer Magaly , Eterovic Agda Karina , Pickering Curtis R. , Pettaway Curtis A.
Published: April 2023

Figure S4 - Mutation patterns in squamous cell carcinomas from head and neck, bladder, lung, esophagus, cervix and penile sites. A) Mutational patterns, inferred by cophenetic correlation, indicated three main mutation signatures defined as: Sq-MP1 - characterized by an enrichment of C>T and C>G changes at TCN context (N = any of the 4 bases), and at lower frequency C>A changes at the same TCN context; Sq-MP2 - characterized by an enrichment of C>T changes, mainly at NCG context; and Sq-MP3 - characterized by an enrichment of C>A changes. B) These mutation patterns were compared to each single base substitution (SBS) signatures (v3) from COSMIC database by estimation of their cosine similarity, represented in the heatmap. Sq-MP1 was highly similar to signatures SBS13 (CS = 0.739). SBS13 signature is attributed to the activity of APOBEC family of cytidine deaminases. Sq-MP2 was highly similar to signatures SBS6 (CS = 0.875). SBS6 is associated with defective mismatch repair system. Sq-MP3 was similar to SBS4 (CS=0.956). SBS4 is linked to exposure to tobacco smoking mutagens.
Supplementary Table S7 from Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer
Authors: Topka Sabine , Steinsnyder Zoe , Ravichandran Vignesh , Tkachuk Kaitlyn , Kemel Yelena , Bandlamudi Chaitanya , Winkel Madsen Mogens , Furberg Helena , Ouerfelli Ouathek , Rudin Charles M. , Iyer Gopa , Lipkin Steven M. , Mukherjee Semanti , Solit David B. , Berger Michael F. , Bajorin Dean F. , Rosenberg Jonathan E. , Taylor Barry S. , de Stanchina Elisa , Vijai Joseph , Offit Kenneth
Published: April 2023

Supplementary Table S7
Supplementary Data from FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions
Authors: Bradford Diana , Larkins Erin , Mushti Sirisha L. , Rodriguez Lisa , Skinner Amy M. , Helms Whitney S. , Price Lauren S.L. , Zirkelbach Jeanne Fourie , Li Yangbing , Liu Jiang , Charlab Rosane , Turcu Francisca Reyes , Liang Dun , Ghosh Soma , Roscoe Donna , Philip Reena , Zack-Taylor Autumn , Tang Shenghui , Kluetz Paul G. , Beaver Julia A. , Pazdur Richard , Theoret Marc R. , Singh Harpreet
Published: April 2023

Supplementary Tables 1 - 3
Supplementary Table from Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Authors: Lassman Andrew B. , Sepúlveda-Sánchez Juan Manuel , Cloughesy Timothy F. , Gil-Gil Miguel J. , Puduvalli Vinay K. , Raizer Jeffrey J. , De Vos Filip Y.F. , Wen Patrick Y. , Butowski Nicholas A. , Clement Paul M.J. , Groves Morris D. , Belda-Iniesta Cristóbal , Giglio Pierre , Soifer Harris S. , Rowsey Steven , Xu Cindy , Avogadri Francesca , Wei Ge , Moran Susan , Roth Patrick
Published: April 2023

Supplementary Table from Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Supplementary Data from Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation
Authors: Hu Nan , Wang Fangyang , Sun Tianyu , Xu Zhengfan , Zhang Jing , Bernard Denzil , Xu Shilin , Wang Shaomeng , Kaminski Mark , Devata Suma , Phillips Tycel , Malek Sami N.
Published: April 2023

Supplementary Figure and Table legends
Supplementary Data Table S1 from Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation
Authors: Hu Nan , Wang Fangyang , Sun Tianyu , Xu Zhengfan , Zhang Jing , Bernard Denzil , Xu Shilin , Wang Shaomeng , Kaminski Mark , Devata Suma , Phillips Tycel , Malek Sami N.
Published: April 2023

Mutations and associated characteristics of 10 FL cases with BTK mutations
Supplementary Table S4 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Authors: Beinat Corinne , Patel Chirag B. , Haywood Tom , Murty Surya , Naya Lewis , Castillo Jessa B. , Reyes Samantha T. , Phillips Megan , Buccino Pablo , Shen Bin , Park Jun Hyung , Koran Mary Ellen I. , Alam Israt S. , James Michelle L. , Holley Dawn , Halbert Kim , Gandhi Harsh , He Joy Q. , Granucci Monica , Johnson Eli , Liu Daniel Dan , Uchida Nobuko , Sinha Rahul , Chu Pauline , Born Donald E. , Warnock Geoffrey I. , Weissman Irving , Hayden-Gephart Melanie , Khalighi Mehdi , Massoud Tarik F. , Iagaru Andrei , Davidzon Guido , Thomas Reena , Nagpal Seema , Recht Lawrence D. , Gambhir Sanjiv Sam
Published: April 2023

Vital signs of the patients administered with [18F]DASA-23
Supplementary Figure S9 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Authors: Beinat Corinne , Patel Chirag B. , Haywood Tom , Murty Surya , Naya Lewis , Castillo Jessa B. , Reyes Samantha T. , Phillips Megan , Buccino Pablo , Shen Bin , Park Jun Hyung , Koran Mary Ellen I. , Alam Israt S. , James Michelle L. , Holley Dawn , Halbert Kim , Gandhi Harsh , He Joy Q. , Granucci Monica , Johnson Eli , Liu Daniel Dan , Uchida Nobuko , Sinha Rahul , Chu Pauline , Born Donald E. , Warnock Geoffrey I. , Weissman Irving , Hayden-Gephart Melanie , Khalighi Mehdi , Massoud Tarik F. , Iagaru Andrei , Davidzon Guido , Thomas Reena , Nagpal Seema , Recht Lawrence D. , Gambhir Sanjiv Sam
Published: April 2023

Imaging of IC-3
Supplementary Table S2 from High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Authors: Sánchez-Guixé Mònica , Hierro Cinta , Jiménez José , Viaplana Cristina , Villacampa Guillermo , Monelli Erika , Brasó-Maristany Fara , Ogbah Zighereda , Parés Mireia , Guzmán Marta , Grueso Judit , Rodríguez Olga , Oliveira Mafalda , Azaro Analía , Garralda Elena , Tabernero Josep , Casanovas Oriol , Scaltriti Maurizio , Prat Aleix , Dienstmann Rodrigo , Nuciforo Paolo , Saura Cristina , Graupera Mariona , Vivancos Ana , Rodon Jordi , Serra Violeta
Published: April 2023

Supplementary Table S2 HTG OBP panel raw data
Supplementary Figure S3 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Authors: Beinat Corinne , Patel Chirag B. , Haywood Tom , Murty Surya , Naya Lewis , Castillo Jessa B. , Reyes Samantha T. , Phillips Megan , Buccino Pablo , Shen Bin , Park Jun Hyung , Koran Mary Ellen I. , Alam Israt S. , James Michelle L. , Holley Dawn , Halbert Kim , Gandhi Harsh , He Joy Q. , Granucci Monica , Johnson Eli , Liu Daniel Dan , Uchida Nobuko , Sinha Rahul , Chu Pauline , Born Donald E. , Warnock Geoffrey I. , Weissman Irving , Hayden-Gephart Melanie , Khalighi Mehdi , Massoud Tarik F. , Iagaru Andrei , Davidzon Guido , Thomas Reena , Nagpal Seema , Recht Lawrence D. , Gambhir Sanjiv Sam
Published: April 2023

Evaluation of PKM2 expression in U87-GFP/luc orthotopic GBM
Supplementary Figure S1 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Authors: Beinat Corinne , Patel Chirag B. , Haywood Tom , Murty Surya , Naya Lewis , Castillo Jessa B. , Reyes Samantha T. , Phillips Megan , Buccino Pablo , Shen Bin , Park Jun Hyung , Koran Mary Ellen I. , Alam Israt S. , James Michelle L. , Holley Dawn , Halbert Kim , Gandhi Harsh , He Joy Q. , Granucci Monica , Johnson Eli , Liu Daniel Dan , Uchida Nobuko , Sinha Rahul , Chu Pauline , Born Donald E. , Warnock Geoffrey I. , Weissman Irving , Hayden-Gephart Melanie , Khalighi Mehdi , Massoud Tarik F. , Iagaru Andrei , Davidzon Guido , Thomas Reena , Nagpal Seema , Recht Lawrence D. , Gambhir Sanjiv Sam
Published: April 2023

[18F]DASA-23 Radiosynthesis
Figure S1 from A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma
Authors: Angeles Christina V. , Velez Ana , Rios Jordan , Laxa Bernadette , Shum David , Ruiz Penelope D. , Shen Yawei , Ostrovnaya Irina , Gularte-Mérida Rodrigo , Nacev Benjamin A. , Dickson Mark A. , Djaballah Hakim , Okada Tomoyo , Singer Samuel
Published: April 2023

Copy number, methylation status, and expression of CEBPA in liposarcoma cell lines.
Supplementary Figure from Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study
Authors: Toulmonde Maud , Brahmi Mehdi , Giraud Antoine , Chakiba Camille , Bessede Alban , Kind Michèle , Toulza Emilie , Pulido Marina , Albert Sabrina , Guégan Jean-Philippe , Cousin Sophie , Mathoulin-Pelissier Simone , Perret Raul , Croce Sabrina , Blay Jean-Yves , Ray-Coquard Isabelle , Floquet Anne , Italiano Antoine
Published: April 2023

Supplementary Figure from Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study
Supplementary Tables from Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma
Authors: Birnbaum David J. , Begg Sebastian K.S. , Finetti Pascal , Vanderburg Charles , Kulkarni Anupriya S. , Neyaz Azfar , Hank Thomas , Tai Eric , Deshpande Vikram , Bertucci François , Birnbaum Daniel , Lillemoe Keith D. , Warshaw Andrew L. , Mino-Kenudson Mari , Fernandez-Del Castillo Carlos , Ting David T. , Liss Andrew S.
Published: April 2023

Supplementary Tables S1-S15
Supplementary Figure from Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer
Authors: Fasching Peter A. , Liu Duan , Scully Steve , Ingle James N. , Lyra Paulo C. , Rack Brigitte , Hein Alexander , Ekici Arif B. , Reis Andre , Schneeweiss Andreas , Tesch Hans , Fehm Tanja N. , Heinrich Georg , Beckmann Matthias W. , Ruebner Matthias , Huebner Hanna , Lambrechts Diether , Madden Ebony , Shen Jess , Romm Jane , Doheny Kim , Jenkins Gregory D. , Carlson Erin E. , Li Liang , Fridley Brooke L. , Cunningham Julie M. , Janni Wolfgang , Monteiro Alvaro N.A. , Schaid Daniel J. , Häberle Lothar , Weinshilboum Richard M. , Wang Liewei
Published: April 2023

Supplementary Figure from Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer
Supplementary Materials from Development and Multiple Validation of the Protein Multi-marker Panel for Diagnosis of Pancreatic Cancer
Authors: Kim Yoseop , Yeo Injoon , Huh Iksoo , Kim Jaenyeon , Han Dohyun , Jang Jin-Young , Kim Youngsoo
Published: April 2023

Supplementary Materials
Supplementary Table from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial
Authors: Zhao Jimmy L. , Fizazi Karim , Saad Fred , Chi Kim N. , Taplin Mary-Ellen , Sternberg Cora N. , Armstrong Andrew J. , de Bono Johann S. , Duggan William T. , Scher Howard I.
Published: April 2023

Supplementary Table from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial
Supplementary Data from A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study
Authors: Zhou Qing , Wu Lin , Hu Pei , An Tongtong , Zhou Jianying , Zhang Li , Liu Xiao-Qing , Luo Feng , Zheng Xin , Cheng Ying , Yang Nong , Li Junling , Feng Jifeng , Han Baohui , Song Yong , Wang Kai , Fang Jian , Zhao Hong , Shu Yongqian , Lin Xiao-Yan , Chen Zhihong , Gan Bin , Xu Wan-Hong , Tang Wei , Zhang Xiaoying , Yang Jin-Ji , Xu Xiao , Wu Yi-Long
Published: April 2023

Supplementary Data from A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study
Supplementary Table 1 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies
Authors: Liang Yi , Jeganathan Sujeeve , Marastoni Stefano , Sharp Adam , Figueiredo Ines , Marcellus Richard , Mawson Amanda , Shalev Zvi , Pesic Aleksandra , Sweet Joan , Guo Haiyang , Uehling David , Gurel Bora , Neeb Antje , He Housheng Hansen , Montgomery Bruce , Koritzinsky Marianne , Oakes Samantha , de Bono Johann S. , Gleave Martin , Zoubeidi Amina , Wouters Bradly G. , Joshua Anthony M.
Published: April 2023

List of antibodies used for Western Blot analyses
Supplementary Figure from Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
Authors: Miller Katherine E. , Cassady Kevin A. , Roth Justin C. , Clements Jennifer , Schieffer Kathleen M. , Leraas Kristen , Miller Anthony R. , Prasad Nripesh , Leavenworth Jianmei W. , Aban Inmaculada B. , Whitley Richard J. , Gillespie G. Yancey , Mardis Elaine R. , Markert James M.
Published: April 2023

Supplementary Figure from Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
Supplementary Fig. S7 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies
Authors: Liang Yi , Jeganathan Sujeeve , Marastoni Stefano , Sharp Adam , Figueiredo Ines , Marcellus Richard , Mawson Amanda , Shalev Zvi , Pesic Aleksandra , Sweet Joan , Guo Haiyang , Uehling David , Gurel Bora , Neeb Antje , He Housheng Hansen , Montgomery Bruce , Koritzinsky Marianne , Oakes Samantha , de Bono Johann S. , Gleave Martin , Zoubeidi Amina , Wouters Bradly G. , Joshua Anthony M.
Published: April 2023

Emergence of ENZ resistance can be prevented by BCL-2 or IKKB inhibitor in vivo and is associated with IKKB upregulation
Supplementary Fig. S5 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies
Authors: Liang Yi , Jeganathan Sujeeve , Marastoni Stefano , Sharp Adam , Figueiredo Ines , Marcellus Richard , Mawson Amanda , Shalev Zvi , Pesic Aleksandra , Sweet Joan , Guo Haiyang , Uehling David , Gurel Bora , Neeb Antje , He Housheng Hansen , Montgomery Bruce , Koritzinsky Marianne , Oakes Samantha , de Bono Johann S. , Gleave Martin , Zoubeidi Amina , Wouters Bradly G. , Joshua Anthony M.
Published: April 2023

Treatment of BCL-2 and IKKB inhibitor decreases cell growth and induces cell death in ENZ-resistant cell lines
Supplementary Data from Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
Authors: Miller Katherine E. , Cassady Kevin A. , Roth Justin C. , Clements Jennifer , Schieffer Kathleen M. , Leraas Kristen , Miller Anthony R. , Prasad Nripesh , Leavenworth Jianmei W. , Aban Inmaculada B. , Whitley Richard J. , Gillespie G. Yancey , Mardis Elaine R. , Markert James M.
Published: April 2023

Supplementary Data from Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study
Supplementary Fig. S2 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies
Authors: Liang Yi , Jeganathan Sujeeve , Marastoni Stefano , Sharp Adam , Figueiredo Ines , Marcellus Richard , Mawson Amanda , Shalev Zvi , Pesic Aleksandra , Sweet Joan , Guo Haiyang , Uehling David , Gurel Bora , Neeb Antje , He Housheng Hansen , Montgomery Bruce , Koritzinsky Marianne , Oakes Samantha , de Bono Johann S. , Gleave Martin , Zoubeidi Amina , Wouters Bradly G. , Joshua Anthony M.
Published: April 2023

IKKB immunohistochemistry validation
Supplementary Fig. S1 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies
Authors: Liang Yi , Jeganathan Sujeeve , Marastoni Stefano , Sharp Adam , Figueiredo Ines , Marcellus Richard , Mawson Amanda , Shalev Zvi , Pesic Aleksandra , Sweet Joan , Guo Haiyang , Uehling David , Gurel Bora , Neeb Antje , He Housheng Hansen , Montgomery Bruce , Koritzinsky Marianne , Oakes Samantha , de Bono Johann S. , Gleave Martin , Zoubeidi Amina , Wouters Bradly G. , Joshua Anthony M.
Published: April 2023

BCL-2 immunohistochemistry validation
Supplementary Data from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung Trial
Authors: Barlesi Fabrice , Tomasini Pascale , Karimi Maryam , Michiels Stefan , Raimbourg Judith , Daniel Catherine , Janicot Henri , Madroszyk Anne , Audigier-Valette Clarisse , Quoix Elisabeth , Mazieres Julien , Moro-Sibilot Denis , Dansin Eric , Molinier Olivier , Morel Hugues , Pichon Eric , Cortot Alexis , Otto Josiane , Chomy François , Souquet Pierre-Jean , Cloarec Nicolas , Giroux-Leprieur Etienne , Bieche Ivan , Lacroix Ludovic , Boyault Sandrine , Attignon Valery , Soubeyran Isabelle , Morel Alain , Tran-Dien Alicia , Jacquet Alexandra , Dall'Olio Filippo Gustavo , Jimenez Marta , Soria Jean-Charles , Besse Benjamin
Published: April 2023

Supplementary Data from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung Trial
Supplementary Figure from Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients
Authors: Zhang Wen , Gong Caifeng , Peng Xuenan , Bi Xinyu , Sun Yongkun , Zhou Jianguo , Wu Fan , Zeng Huiying , Wang Yan , Zhou Hui , Zhao Hong , Cai Jianqiang , Zhou Aiping
Published: April 2023

Supplementary Figure from Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients
Supplementary Data from A Cathepsin-Targeted Quenched Activity–Based Probe Facilitates Enhanced Detection of Human Tumors during Resection
Authors: Kennedy Gregory T. , Holt David E. , Azari Feredun S. , Bernstein Elizabeth , Nadeem Bilal , Chang Ashley , Sullivan Neil T. , Segil Alix , Desphande Charuhas , Bensen Eric , Santini John T. , Kucharczuk John C. , Delikatny Edward J. , Bogyo Matthew , Egan A.J. Matthew , Bradley Charles W. , Eruslanov Evgeniy , Lickliter Jason D. , Wright Gavin , Singhal Sunil
Published: April 2023

Supplementary Data from A Cathepsin-Targeted Quenched Activity–Based Probe Facilitates Enhanced Detection of Human Tumors during Resection
Supplementary Data from Large-Scale In Vitro and In Vivo CRISPR-Cas9 Knockout Screens Identify a 16-Gene Fitness Score for Improved Risk Assessment in Acute Myeloid Leukemia
Authors: Jin Peng , Jin Qiqi , Wang Xiaoling , Zhao Ming , Dong Fangyi , Jiang Ge , Li Zeyi , Shen Jie , Zhang Wei , Wu Shishuang , Li Ran , Zhang Yunxiang , Li Xiaoyang , Li Junmin
Published: April 2023

Supplementary Data from Large-Scale In Vitro and In Vivo CRISPR-Cas9 Knockout Screens Identify a 16-Gene Fitness Score for Improved Risk Assessment in Acute Myeloid Leukemia
Supplementary Data from Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
Authors: Johannet Paul , Liu Wenke , Fenyo David , Wind-Rotolo Megan , Krogsgaard Michelle , Mehnert Janice M. , Weber Jeffrey S. , Zhong Judy , Osman Iman
Published: April 2023

Supplementary Data from Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
Supplementary Figure from Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer
Authors: Bando Hideaki , Tsukada Yuichiro , Inamori Koji , Togashi Yosuke , Koyama Shohei , Kotani Daisuke , Fukuoka Shota , Yuki Satoshi , Komatsu Yoshito , Homma Shigenori , Taketomi Akinobu , Uemura Mamoru , Kato Takeshi , Fukui Makoto , Wakabayashi Masashi , Nakamura Naoki , Kojima Motohiro , Kawachi Hiroshi , Kirsch Richard , Yoshida Tsutomu , Suzuki Yutaka , Sato Akihiro , Nishikawa Hiroyoshi , Ito Masaaki , Yoshino Takayuki
Published: April 2023

Supplementary Figure from Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer
Supplementary Figure from Post-transplant Malignancies Show Reduced T-cell Abundance and Tertiary Lymphoid Structures as Correlates of Impaired Cancer Immunosurveillance
Authors: Datta Rabi R. , Schran Simon , Persa Oana-Diana , Aguilar Claire , Thelen Martin , Lehmann Jonas , Garcia-Marquez Maria A. , Wennhold Kerstin , Preugszat Ella , Zentis Peter , von Bergwelt-Baildon Michael S. , Quaas Alexander , Bruns Christiane J. , Kurschat Christine , Mauch Cornelia , Löser Heike , Stippel Dirk L. , Schlößer Hans A.
Published: April 2023

Supplementary Figure from Post-transplant Malignancies Show Reduced T-cell Abundance and Tertiary Lymphoid Structures as Correlates of Impaired Cancer Immunosurveillance
Supplementary Table from The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Authors: Ma Cynthia X. , Luo Jingqin , Freedman Rachel A. , Pluard Timothy J. , Nangia Julie R. , Lu Janice , Valdez-Albini Frances , Cobleigh Melody , Jones Jason M. , Lin Nancy U. , Winer Eric P. , Marcom P. Kelly , Thomas Shana , Anderson Jill , Haas Brittney , Bucheit Leslie , Bryce Richard , Lalani Alshad S. , Carey Lisa A. , Goetz Matthew P. , Gao Feng , Kimmick Gretchen , Pegram Mark D. , Ellis Matthew J. , Bose Ron
Published: April 2023

Supplementary Table from The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Supplementary Figure from The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Authors: Ma Cynthia X. , Luo Jingqin , Freedman Rachel A. , Pluard Timothy J. , Nangia Julie R. , Lu Janice , Valdez-Albini Frances , Cobleigh Melody , Jones Jason M. , Lin Nancy U. , Winer Eric P. , Marcom P. Kelly , Thomas Shana , Anderson Jill , Haas Brittney , Bucheit Leslie , Bryce Richard , Lalani Alshad S. , Carey Lisa A. , Goetz Matthew P. , Gao Feng , Kimmick Gretchen , Pegram Mark D. , Ellis Matthew J. , Bose Ron
Published: April 2023

Supplementary Figure from The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Supplementary Table from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma
Authors: Zhang Mingzhi , Chen Dan , Fu Xiaorui , Meng Huimin , Nan Feifei , Sun Zhenchang , Yu Hui , Zhang Lei , Li Ling , Li Xin , Wang Xinhua , Wang Min , You Fengtao , Li Zhaoming , Chang Yu , Zhou Zhiyuan , Yan Jiaqin , Li Jiwei , Wu Xiaolong , Wang Yu , Wang Yinyan , Xiang Shufen , Chen YuSheng , Pan Guifang , Xu Hanying , Zhang Bozhen , Yang Lin
Published: April 2023

Supplementary Table from Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma